Other equities research analysts also recently issued reports about the company. HSBC set a CHF 88 target price on Novartis and gave the company a neutral rating in a report on Monday, July 22nd. Credit Suisse Group set a CHF 88 target price on Novartis and gave the company a neutral rating in a report on Friday, July 19th. UBS Group set a CHF 90 target price on Novartis and gave the company a neutral rating in a report on Tuesday, September 10th. Goldman Sachs Group set a CHF 105 target price on Novartis and gave the company a buy rating in a report on Friday, August 30th. Finally, Kepler Capital Markets set a CHF 87 target price on Novartis and gave the company a buy rating in a report on Tuesday, May 21st. Three investment analysts have rated the stock with a sell rating, four have issued a hold rating and six have issued a buy rating to the company. Novartis currently has a consensus rating of Hold and an average target price of CHF 90.85.
Novartis has a twelve month low of CHF 72.45 and a twelve month high of CHF 88.30.
Novan, Inc, a clinical-stage biotechnology company, focuses on the development and commercialization of nitric oxide-based therapies to treat dermatological and oncovirus-mediated diseases. Its clinical stage product candidates include SB204, a topical monotherapy that is in Phase III pivotal clinical trials for the treatment of acne vulgaris; and SB206, a topical antiviral gel, which is in Phase III pivotal trials for the treatment of patients with external genital warts, and Phase II clinical trial for the treatment of molluscum contagiosum.
Recommended Story: What does the Dogs of the Dow mean?
Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.